MA49377A - Utilisation d'anticorps anti-cd70 argx-110 pour traiter la leucémie myéloïde aiguë - Google Patents

Utilisation d'anticorps anti-cd70 argx-110 pour traiter la leucémie myéloïde aiguë

Info

Publication number
MA49377A
MA49377A MA049377A MA49377A MA49377A MA 49377 A MA49377 A MA 49377A MA 049377 A MA049377 A MA 049377A MA 49377 A MA49377 A MA 49377A MA 49377 A MA49377 A MA 49377A
Authority
MA
Morocco
Prior art keywords
argx
antibodies
myeloid leukemia
acute myeloid
treat acute
Prior art date
Application number
MA049377A
Other languages
English (en)
Inventor
Haard Hans De
Nicolas Leupin
Adrian Ochsenbein
Carsten Riether
Rompaey Luc Van
Original Assignee
Argenx Bvba
Univ Of Bern
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Argenx Bvba, Univ Of Bern filed Critical Argenx Bvba
Publication of MA49377A publication Critical patent/MA49377A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001136—Cytokines
    • A61K39/001138—Tumor necrosis factors [TNF] or CD70
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
MA049377A 2017-06-16 2018-06-18 Utilisation d'anticorps anti-cd70 argx-110 pour traiter la leucémie myéloïde aiguë MA49377A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB1709677.7A GB2567613A (en) 2017-06-16 2017-06-16 Treatment for acute myeloid leukaemia

Publications (1)

Publication Number Publication Date
MA49377A true MA49377A (fr) 2020-04-22

Family

ID=59462340

Family Applications (1)

Application Number Title Priority Date Filing Date
MA049377A MA49377A (fr) 2017-06-16 2018-06-18 Utilisation d'anticorps anti-cd70 argx-110 pour traiter la leucémie myéloïde aiguë

Country Status (16)

Country Link
US (1) US20190106498A1 (fr)
EP (1) EP3638696B1 (fr)
JP (1) JP2020528044A (fr)
KR (1) KR20200024823A (fr)
CN (1) CN110730789A (fr)
AU (2) AU2018285731B2 (fr)
BR (1) BR112019026795A2 (fr)
CA (1) CA3063694A1 (fr)
EA (1) EA202090061A1 (fr)
GB (2) GB2567613A (fr)
IL (1) IL271266A (fr)
JO (1) JOP20190285A1 (fr)
MA (1) MA49377A (fr)
MX (1) MX2019015204A (fr)
PH (1) PH12019502477A1 (fr)
WO (1) WO2018229303A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE039849T2 (hu) 2011-03-16 2019-02-28 Argenx Bvba CD70 elleni ellenanyagok
US10391168B1 (en) 2014-08-22 2019-08-27 University Of Bern Anti-CD70 combination therapy
GB201800649D0 (en) 2018-01-16 2018-02-28 Argenx Bvba CD70 Combination Therapy
TW202038958A (zh) 2018-12-18 2020-11-01 比利時商阿根思公司 Ｃｄ７０組合治療
SG11202110702WA (en) * 2019-04-29 2021-11-29 Immunogen Inc Therapeutic combinations comprising anti-cd123 immunoconjugates
WO2021055437A1 (fr) * 2019-09-16 2021-03-25 The General Hospital Corporation Cellules t de récepteurs antigéniques chimériques (car) ciblées cd70 et leurs utilisations
TW202138388A (zh) * 2019-12-30 2021-10-16 美商西根公司 以非海藻糖苷化抗－ｃｄ７０抗體治療癌症之方法
EP4173638A1 (fr) * 2020-06-30 2023-05-03 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Anticorps anti-cd70 et son application
CN116249519A (zh) 2020-08-29 2023-06-09 阿根思有限公司 治疗对bcl-2抑制剂具有降低的敏感性的患者的方法
CN114720358B (zh) * 2022-04-11 2022-09-27 浙江普罗亭健康科技有限公司 一种质谱流式血液肿瘤免疫分型中替代侧向散射光信号的抗体组合及应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5356648B2 (ja) 2003-02-20 2013-12-04 シアトル ジェネティックス， インコーポレイテッド 抗ｃｄ７０抗体−医薬結合体、ならびに癌および免疫障害の処置のためのそれらの使用
WO2006113909A2 (fr) 2005-04-19 2006-10-26 Seattle Genetics, Inc. Agents de liaison anti-cd70 humanises et utilisations
AU2005295595C1 (en) 2004-10-15 2012-06-21 Seattle Genetics, Inc. Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
EP1934261B1 (fr) * 2005-09-26 2014-10-29 Medarex, L.L.C. Anticorps monoclonaux humains diriges contre cd70
WO2008074004A2 (fr) 2006-12-14 2008-06-19 Medarex, Inc. Anticorps humains se liant à cd70 et utilisations de ceux-ci
HUE039849T2 (hu) * 2011-03-16 2019-02-28 Argenx Bvba CD70 elleni ellenanyagok
RS56169B1 (sr) * 2013-02-14 2017-11-30 Bristol Myers Squibb Co Jedinjenja tubulisina, metode pripreme i primena
BR112018008904A2 (pt) * 2015-11-03 2018-11-27 Janssen Biotech Inc anticorpos que se ligam especificamente a tim-3 e seus usos

Also Published As

Publication number Publication date
IL271266A (en) 2020-01-30
CA3063694A1 (fr) 2018-12-20
EA202090061A1 (ru) 2020-04-13
MX2019015204A (es) 2020-08-17
JP2020528044A (ja) 2020-09-17
GB2567613A (en) 2019-04-24
BR112019026795A2 (pt) 2020-06-30
CN110730789A (zh) 2020-01-24
AU2018285731A1 (en) 2019-11-28
GB201709677D0 (en) 2017-08-02
AU2018285731B2 (en) 2021-11-04
GB201712273D0 (en) 2017-09-13
AU2022200521A1 (en) 2022-02-17
US20190106498A1 (en) 2019-04-11
JOP20190285A1 (ar) 2019-12-15
KR20200024823A (ko) 2020-03-09
WO2018229303A1 (fr) 2018-12-20
PH12019502477A1 (en) 2020-07-20
EP3638696B1 (fr) 2024-03-06
EP3638696A1 (fr) 2020-04-22

Similar Documents

Publication Publication Date Title
MA49377A (fr) Utilisation d'anticorps anti-cd70 argx-110 pour traiter la leucémie myéloïde aiguë
MA55629A (fr) Compositions d'anticorps pour le traitement de tumeurs
MA55697A (fr) Molécules d'anticorps pour le traitement du cancer
MA42043A (fr) Anticorps anti-ox40 et procédés d'utilisation de ceux-ci
MA45481A (fr) Utilisation d'exosomes pour le traitement de maladies
MA43018A (fr) Anticorps anti-pd1 et procédés d'utilisation
MA44146A (fr) Combinaison d'anticorps anti-pd-1 et d'anticorps bispécifiques anti-cd20/anti-cd3 pour traiter le cancer
MA42925A (fr) Anticorps anti-tigit et méthodes d'utilisation
MA41294A (fr) Anticorps anti-myostatine, polypeptides contenant des variants de régions fc, et procédés d'utilisation
MA40682B1 (fr) Anticorps anti-ox40 et procédés d'utilisation correspondants
MA48579A (fr) Anticorps anti-pd1 et méthodes d'utilisation de ceux-ci
MA42243A (fr) Anticorps de facteur xi et méthodes d'utilisation
MA47719A (fr) Esketamine pour le traitement de la dépression
MA43197A (fr) Constructions d'anticorps bispécifiques pour cdh3 et cd3
MA51032A (fr) Utilisation d'antagonistes de fcrn pour le traitement de la myasthénie grave généralisée
MA47604A (fr) Anticorps anti-pd-1 pour le traitement du cancer du poumon
MA51873A (fr) Molécules probiotiques pour réduire la virulence d'agents pathogènes
MA46180A (fr) Analogues de l'amyline
MA49401A (fr) Inhibiteurs de la kinase alk2 contenant de l'imidazole
MA51337A (fr) Inhibiteurs spiro exo-aza de l'interaction ménine-mll
MA46892A (fr) Composés d'alcène tétrasubstitués et leur utilisation pour le traitement du cancer du sein
FR3022462B1 (fr) Composition orale d'anticorps anti-tnfalpha
MA49781A (fr) Expression directe d'anticorps
MA40512A (fr) Anticorps de l'angiopoïétine-like 4 et procédés d'utilisation correspondants
MA43825A (fr) Schémas posologiques pour le traitement d'infections fongiques